Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-18
2011-01-18
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S235000
Reexamination Certificate
active
07872034
ABSTRACT:
The invention relates to arylcycloalkyl-substituted alkanoic acid derivatives and to their physiologically acceptable salts and physiologically functional derivatives.What is described are compounds of the formula I,in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable, for example, for the treatment and/or prevention of disorders of the fatty acid metabolism and glucose utilization disorders and also disorders in which insulin resistance is involved.
REFERENCES:
patent: 5130770 (1992-07-01), Blanc et al.
patent: 6221633 (2001-04-01), Ertl
patent: 6221897 (2001-04-01), Frick et al.
patent: 6245744 (2001-06-01), Frick et al.
patent: 6277831 (2001-08-01), Frick
patent: 6342512 (2002-01-01), Kirsch
patent: 6506778 (2003-01-01), Defossa
patent: 6566390 (2003-05-01), Baringhaus
patent: 6569835 (2003-05-01), Frick et al.
patent: 6699904 (2004-03-01), Hayward et al.
patent: 6897198 (2005-05-01), Frick et al.
patent: 6908926 (2005-06-01), Dorwald et al.
patent: WO 94/18183 (1994-08-01), None
patent: WO 94/18184 (1994-08-01), None
patent: WO 96/38428 (1996-12-01), None
patent: WO 97/26265 (1997-07-01), None
patent: WO 97/41097 (1997-11-01), None
patent: WO 98/08871 (1998-03-01), None
patent: WO 98/19998 (1998-05-01), None
patent: WO 99/03861 (1999-01-01), None
patent: WO 99/15525 (1999-04-01), None
patent: WO 99/61431 (1999-12-01), None
patent: WO 99/62871 (1999-12-01), None
patent: WO 99/62872 (1999-12-01), None
patent: WO 99/67278 (1999-12-01), None
patent: WO 99/67279 (1999-12-01), None
patent: WO 00/40569 (2000-07-01), None
patent: WO 00/64876 (2000-11-01), None
patent: WO 00/64888 (2000-11-01), None
patent: WO 00/66585 (2000-11-01), None
patent: WO 00/71549 (2000-11-01), None
patent: WO 00/78312 (2000-12-01), None
patent: WO 01/04146 (2001-01-01), None
patent: WO 01/09111 (2001-02-01), None
patent: WO 01/21602 (2001-03-01), None
patent: WO 01/40169 (2001-06-01), None
patent: WO 01/40171 (2001-06-01), None
patent: WO 01/72290 (2001-10-01), None
patent: WO 01/81327 (2001-11-01), None
patent: WO 01/83451 (2001-11-01), None
patent: WO 01/85695 (2001-11-01), None
patent: WO 01/91752 (2001-12-01), None
patent: WO 02/18355 (2002-03-01), None
patent: WO 02/38541 (2002-05-01), None
patent: WO 02/46146 (2002-06-01), None
patent: WO 02/50027 (2002-06-01), None
patent: WO 02/059098 (2002-08-01), None
patent: WO 02/096864 (2002-12-01), None
patent: WO 03/004458 (2003-01-01), None
patent: WO 03/011819 (2003-02-01), None
patent: WO 03/020269 (2003-03-01), None
patent: WO 03/040174 (2003-05-01), None
patent: WO 03/066581 (2003-08-01), None
patent: WO 03/084922 (2003-10-01), None
patent: WO 03/084923 (2003-10-01), None
patent: WO 03/104188 (2003-12-01), None
patent: WO 2004/004665 (2004-01-01), None
Asakawa A et al., Cocaine-Amphetamine-Regulated Transcript Influences Energy Metabolism Anxiety and Gastric Emptying in Mice, Hormone and Metabolic Reserch; vol. 33(9); 2001; pp. 554-558.
Berger Joel et al., The Mechanisms of Action of PPARs, Annul. Rev. Med.; vol. 53; 2002; pp. 409-435.
Fruchart Jean-Charles et al., PPARs, Metabolic Disease and Atherosclerosis, Pharmacological Research; vol. 44, No. 5; 2001' pp. 345-352.
Kersten Sander et al., Roles of PPARs in Health and Disease, Nature; vol. 405; May 25, 2000; pp. 421-424.
Kliewer Steven A et al., Peroxisome Proliferator-Activated Receptors: From Genes to Physiology, Recent Prog. Horm Res.; vol. 56; 2001; pp. 239-263.
Lee Daniel W et al., Leptin agonists as a potential approach to the treatment of obesity, Drugs of the Future; vol. 26(9); 2001; pp. 873-881.
Motojima Kiyoto, Peroxisome Proliferator-Activated Receptor (PPAR): Structure, Mechanisms of Activation and Diverse Functions, Cell Structure and Function; vol. 18; 1993; pp. 267-277.
Okada Hiroshi et al., Synthesis and Antitumor Activities of Prodrugs of Benzoylphenylureas, Chem. Pharm. Bull.; vol. 42(1); 1994; pp. 57-61.
Pineda Torra Ines et al., Peroxisome Proliferator-activated Receptors: from Transcriptional Control to Clinical Practice, Curr. Opin. Lipidol; vol. 12; 2001; pp. 245-254.
Pineda Torra Ines et al., Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging, Curr. Opin. Lipidol; vol. 10; 1999; pp. 151-159.
Vidal-Puig A et al., Regulation of PPAR y Gene Expression by Nutrition and Obesity in Rodents, J. Clin. Invest.; vol. 97, No. 11, 1996; pp. 2553-2561.
Wilson Timothy M. et al., The PPARs: From Orphan Receptors to Drug Discovery, Journal of Medicinal Chemistry; vol. 43, No. 4; 2000; pp. 527-550.
Zunft H,. J. F. et al., Carob Pulp Preparation for Treatment of Hypercholesterolemia, Advances in Natural Therapy; vol. 18, No. 5; Sep.-Oct. 2001; pp. 230-236.
Falk Eugen
Glombik Heiner
Goerlitzer Jochen
Gretzke Dirk
Keil Stefanie
Farquharson-Torres Serena
Saeed Kamal A
Sanofi-Aventis Deutschland GmbH
LandOfFree
Arylcycloalkyl-substituted alkanoic acid derivatives,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Arylcycloalkyl-substituted alkanoic acid derivatives,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arylcycloalkyl-substituted alkanoic acid derivatives,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2727325